Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Open accessPublished version of a preprint
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Mapping antibody escape in SARS-CoV-2: Several antibodies are in use or under development as therapies to treat COVID-19. As new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants emerge, it is important to predict whether they will remain susceptible to antibody treatment. Starr et al. used a yeast library that covers all mutations to the SARS-CoV-2 receptor-binding domain that do not strongly disrupt binding to the host receptor (ACE2) and mapped how these mutations affect binding to three leading anti–SARS-CoV-2 antibodies. The maps identify mutations that escape antibody binding, including a single mutation that escapes both antibodies in the Regeneron antibody cocktail. Many of the mutations that escape single antibodies are circulating in the human population. Science , this issue p. 850
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Escape maps are consistent with viral mutations selected in cell culture and a persistently infected patient. (A) Viral escape mutations selected by Regeneron with spike-pseudotyped VSV in cell culture in the presence of antibody (12). (B) Escape maps like those in Fig. 1A, but showing only mutations accessible by single-nucleotide changes to the Wuhan-Hu-1 sequence, with nongray colors indicating mutations in cell culture (red), the infected patient (blue), or both (purple). Figure S5 shows these maps colored by how mutations affect ACE2 affinity or RBD expression. (C) Dynamics of RBD mutations in a patient treated with REGN-COV2 at day 145 of infection (black dot-dash vertical line). E484A rose in frequency in linkage with F486I, but because E484A is not an escape mutation in our maps, it is not shown in other panels. See also fig. S4. (D) The escape mutations that arise in cell culture and the infected patient are single-nucleotide–accessible and escape antibody binding without imposing a large cost on ACE2 affinity [as measured using yeast display (7)]. Each point is a mutation, with shape and color indicating whether it is accessible and selected during viral growth. Points farther to the right on the x axis indicate stronger escape from antibody binding; points higher up on the y axis indicate higher ACE2 affinity.](https://figures.cochat.ai/paper-figures/91cf075ab18741e0a80bfb01ad2b708a/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-2.jpg)

![Fig. 4 Structural context of escape mutations. (A) Escape maps projected on antibody-bound RBD structures. [REGN10933 and REGN10987: Protein Data Bank (PDB) ID 6XDG (11); LY-CoV016: PDB ID 7C01 (13)]. Antibody heavy- and light-chain variable domains are shown as blue cartoons, and the RBD surface is colored to indicate how strongly mutations at that site mediate escape (white indicates no escape, red indicates strongest escape site for that antibody or cocktail). Sites where no mutations are functionally tolerated are colored gray. (B) For each antibody, sites were classified as direct antibody contacts (non-hydrogen atoms within 4 Å of antibody), antibody-proximal (4 to 8 Å), or antibody-distal (>8 Å). Each point indicates a site, classified as escape (red) or non-escape (black). The dashed gray line indicates the cutoff used to classify sites as escape or non-escape (see materials and methods for details). Red and black numbers indicate how many sites in each category are escape or non-escape sites, respectively. Interactive visualizations are at https://jbloomlab.github.io/SARS-CoV-2-RBD_MAP_clinical_Abs/, and hypothesized mechanisms of escape and additional structural details for labeled points are shown in fig. S6.](https://figures.cochat.ai/paper-figures/854cbba408614d74b93381682c26dd9e/prospective-mapping-of-viral-mutations-that-escape-antibodies-used-to-treat-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A475V is resistant to class 1 antibodies (structurally defined as described29); E484K and Q493R are resistant to class 2 antibodies7,8,12,13,29,30,32,33; while R346S, N439K, and N440K are resistant to class 3 antibodies7,8,12,13,29,33.”
From mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants (2021) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several of the RBD mutations directly affect angiotensin-converting enzyme 2 (ACE2) receptor-binding affinity, which may affect infectivity, viral load, or transmissibility.11, 12, 13, 14”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations found in emergent S variants decrease sensitivity to neutralization by mAbs, convalescent plasma, and sera from vaccinated individuals (27, 37, 58, 61–70).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The B.1.1.7, B.1.351, and P.1 lineages all harbor a N501Y mutation in the RBD, which increases the affinity for the ACE2 receptor (57, 58), and a D614G mutation, which increases virion spike density, infectivity, and transmissibility (59, 60).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We tested four clinically approved monoclonal antibodies that target the RBD 18,19 (bamlanivimab (LY-CoV555), etesevimab (LY-CoV016), casirivimab (REGN10933) and imdevimab (REGN10987))”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAFFT Multiple Sequence Alignment Software Version 7: Improvements in Performance and Usability
Katoh, K., & Standley, D. M. (2013) · Molecular Biology and Evolution · doi:10.1093/molbev/mst010 · Cited by 46,209
fastp: an ultra-fast all-in-one FASTQ preprocessor
Chen, S., Zhou, Y., Chen, Y., & Gu, J. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty560 · Cited by 29,721
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586
Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM
Li, H. (2013) · DROPS (Schloss Dagstuhl – Leibniz Center for Informatics) · doi:10.48550/arxiv.1303.3997 · Cited by 5,159
Aligning sequence reads, clone sequences and assembly con*gs with BWA-MEM
Li, H. (2014) · arXiv (Cornell University) · doi:10.6084/m9.figshare.963153.v1 · Cited by 4,932
Structural basis of receptor recognition by SARS-CoV-2
Shang, J., Ye, G., Shi, K., Wan, Y., Luo, C., Aihara, H., Geng, Q., Auerbach, A., & Li, F. (2020) · Nature · doi:10.1038/s41586-020-2179-y · Cited by 3,661
Snakemake—a scalable bioinformatics workflow engine
Köster, J., & Rahmann, S. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts480 · Cited by 2,780
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Research works printed but not linked: 2
- 10.1016/j.cell.2020.02.058 · doi:10.1016/j.cell.2020.02.058 · Paper page
- Regeneron Pharmaceuticals Inc. “Regeneron’s casirivimab and imdevimab antibody cocktail for COVID-19 is first combination therapy to receive FDA emergency use authorization ” press release (21 November 2020); https://investor.regeneron.com/news-releases/news-release-details/regenerons-regen-cov2-first-antibody-cocktail-covid-19-receive/.
Cited by
Items 301–400 of 750
Molecular Perspectives of SARS-CoV-2: Pathology, Immune Evasion, and Therapeutic Interventions
Shah, M., & Woo, H. G. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0026 · Cited by 23
Jiang, W., Wang, J., Jiao, S., Gu, C., Xu, W., Chen, B., Wang, R., Chen, H., Xie, Y., Wang, A., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1953683 · Cited by 25
Uncovering a conserved vulnerability site in SARS‐CoV‐2 by a human antibody
Li, T., Cai, H., Zhao, Y., Li, Y., Lai, Y., Yao, H., Liu, L. D., Sun, Z., van Vlissingen, M. F., Kuiken, T., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114544 · Cited by 25
Self-citationEx vivo and in vivo suppression of SARS-CoV-2 with combinatorial AAV/RNAi expression vectors
Becker, J., Stanifer, M. L., Leist, S. R., Stolp, B., Maiakovska, O., West, A., Wiedtke, E., Börner, K., Ghanem, A., Ambiel, I., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.024 · Cited by 25
Lu, J., Yin, Q., Pei, R., Zhang, Q., Qu, Y., Pan, Y., Sun, L., Gao, D., Liang, C., Yang, J., et al. (2022) · Virologica Sinica · doi:10.1016/j.virs.2022.02.005 · Cited by 25
Self-citationRapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
Tanaka, S., Olson, C. A., Barnes, C. O., Higashide, W., Gonzalez, M. R., Taft, J. D., Richardson, A., Martín-Fernández, M., Bogunovic, D., Gnanapragasam, P. N. P., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110348 · Cited by 20
Invernizzi, L., Moyo, P., Cassel, J. A., Isaacs, F. J., Salvino, J. M., Montaner, L. J., Tietjen, I., & Maharaj, V. J. (2022) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-022-04041-3 · Cited by 24
Genomic surveillance, evolution and global transmission of SARS-CoV-2 during 2019–2022
Sharif, N., Alzahrani, K. J., Ahmed, S. N., Khan, A., Banjer, H. J., Alzahrani, F. M., Parvez, A. K., & Dey, S. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0271074 · Cited by 30
Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors
Weidenbacher, P. A. B., Waltari, E., Kobara, I. D. L. R., Bell, B. N., Morris, M. K., Cheng, Y.-C., Hanson, C. V., Pak, J. E., & Kim, P. S. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01140-1 · Cited by 26
Biology of the SARS-CoV-2 Coronavirus
Mingaleeva, R. N., Nigmatulina, N. A., Sharafetdinova, L. M., Romozanova, A. M., Gabdoulkhakova, A. G., Filina, Y. V., Фирнаялович, Ш. Р., Rizvanov, A. A., & Рифкатовна, М. Р. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922120215 · Cited by 41
Tu, Y., Hayat, T., Hobiny, A. D., & Meng, X. (2023) · Applied Mathematical Modelling · doi:10.1016/j.apm.2023.02.002 · Cited by 27
Addetia, A., Park, Y., Starr, T. N., Greaney, A. J., Sprouse, K. R., Bowen, J. E., Tilles, S. W., Voorhis, W. C. V., Bloom, J. D., Corti, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112621 · Cited by 24
Self-citationInsights into next generation sequencing guided antibody selection strategies
Erasmus, M. F., Ferrara, F., D’Angelo, S., Spector, L. P., Leal‐Lopes, C., Teixeira, A. A. R., Sørensen, J., Nagpal, S., Perea‐Schmittle, K., Choudhary, A. K., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-45538-w · Cited by 24
“The antibody binding modes for any SPR-defined bin can vary significantly and are best revealed using detailed epitope analysis techniques, such as alanine scanning, deep mutational scanning 25–27 , or deep mutational learning 28 .”
BackgroundPredicting potential SARS-CoV-2 mutations of concern via full quantum mechanical modelling
Zaccaria, M., Genovese, L., Lawhorn, B. E., Dawson, W., Joyal, A. S., Hu, J., Autissier, P., Nakajima, T., Johnson, W. E., Fofana, I., et al. (2024) · Journal of The Royal Society Interface · doi:10.1098/rsif.2023.0614 · Cited by 21
Karim, F., Riou, C., Bernstein, M. P., Jule, Z., Lustig, G., van Graan, S., Keeton, R., Upton, J., Ganga, Y., Khan, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46673-2 · Cited by 31
Local memory CD4 T cell niches in respiratory viral infection
Pruner, K. B., & Pepper, M. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201733 · Cited by 23
Jawalagatti, V., Kirthika, P., Park, J.-Y., Hewawaduge, C., & Lee, J. H. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.07.007 · Cited by 25
Beeraka, N. M., Sukocheva, O. A., Lukina, E., Liu, J., & Fan, R. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2346 · Cited by 23
Targeted escape of SARS-CoV-2 in vitro from monoclonal antibody S309, the precursor of sotrovimab
Magnus, C. L., Hiergeist, A., Schuster, P., Rohrhofer, A., Medenbach, J., Gessner, A., Peterhoff, D., & Schmidt, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.966236 · Cited by 24
Pattabiraman, C., Prasad, P., George, A. K., Sreenivas, D., Rasheed, R., Reddy, N. V. K., Desai, A. S., & Ravi, V. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16768.1 · Cited by 21
Xiong, D., Zhao, X., Luo, S., Cong, Y., Zhang, J. Z. H., & Duan, L. (2022) · The Journal of Physical Chemistry Letters · doi:10.1021/acs.jpclett.2c00912 · Cited by 24
Chang, M., Tomasovic, L. M., Kuzmina, N. A., Ronk, A. J., Byrne, P. O., Johnson, R. I., Storm, N., Olmedillas, E., Hou, Y. J., Schäfer, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33030-4 · Cited by 22
Computational design of vaccine immunogens
Castro, K. M., Scheck, A., Xiao, S., & Correia, B. E. (2022) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2022.102821 · Cited by 25
A potent and broad neutralization of SARS-CoV-2 variants of concern by DARPins
Chonira, V., Kwon, Y. D., Gorman, J., Case, J. B., Ku, Z., Simeon, R. L., Casner, R. G., Harris, D. R., Olia, A. S., Stephens, T., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01193-2 · Cited by 26
Multi-omics for COVID-19: driving development of therapeutics and vaccines
Guo, M., Xiong, M., Peng, J., Guan, T., Su, H., Huang, Y., Yang, C., Li, Y., Boraschi, D., Pillaiyar, T., et al. (2023) · National Science Review · doi:10.1093/nsr/nwad161 · Cited by 24
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice
Keng, C. T., Yogarajah, T., Lee, R. C. H., Muhammad, I. B. H., Chia, B. S., Vasandani, S. R., Lim, D. S., Guo, K., Wong, Y. H., Mok, C. K., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104682 · Cited by 29
COV2Var, a function annotation database of SARS-CoV-2 genetic variation
Feng, Y., Yi, J., Yang, L., Wang, Y., Wen, J., Zhao, W., Kim, P., & Zhou, X. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad958 · Cited by 26
“We utilized the results of deep mutational scanning experi-D 704 Nucleic Acids Research , 2024, Vol. 52 , Database issue ments to prospectively measure how viral mutations impact antibody binding or neutralization ( 32–34 ).”
MethodPetrenko, V. A., Gillespie, J. W., Plano, L. M. D., & Shokhen, M. (2022) · Viruses · doi:10.3390/v14020384 · Cited by 25
Application of omics technology to combat the COVID‐19 pandemic
Yang, J., Yan, Y., & Zhong, W. (2021) · MedComm · doi:10.1002/mco2.90 · Cited by 21
Bozdaganyan, M. E., Sokolova, O. S., Шайтан, К. В., Kirpichnikov, M. P., & Orekhov, P. S. (2022) · Viruses · doi:10.3390/v14020295 · Cited by 21
Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy
Damavandi, A. R., Dowran, R., Sharif, S. A., Kashanchi, F., & Jafari, R. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00729-6 · Cited by 23
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibodyPreprint
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., di Iulio, J., Wang, Z., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.07.438818 · Cited by 22
“…were labelled at 59 ng/mL S2X259 antibody (the EC90 for binding to yeast-displayed SARS-CoV-2 RBD determined in isogenic pilot binding experiments), and fluorescence-activated cell sorting (FACS) was used to select RBD+ cells that exhibit reduced antibody binding as previously described 32, 60 .”
Self-citationStarr, T. N., Czudnochowski, N., Zatta, F., Park, Y., Liu, Z., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.06.438709 · Cited by 24
Self-citationEpitope mapping via in vitro deep mutational scanning methods and its applications
Keen, M. M., Keith, A. D., & Ortlund, E. A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108072 · Cited by 20
Jeda, A. S., Abbassi, S., Mousavizadeh, A., Esghaie, M., Bokharaei‐Salim, F., Jeddi, F., Shafaati, M., & Abdoli, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108232 · Cited by 26
Anwar, M. Z., Lodhi, M. S., Khan, M. T., Khan, M. I., & Sharif, S. (2022) · Genes · doi:10.3390/genes13030552 · Cited by 21
Cantoni, D. M., Neto, M. M., Thakur, N., Elrefaey, A. M. E., Newman, J., Vishwanath, S., Nadesalingam, A., Chan, A. C. Y., Smith, P., Castillo‐Olivares, J., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03325-9 · Cited by 22
Yeast Surface Display: New Opportunities for a Time-Tested Protein Engineering System
Raeeszadeh‐Sarmazdeh, M., & Boder, E. T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2285-8_1 · Cited by 19
A spatial vaccination strategy to reduce the risk of vaccine-resistant variants
Zhang, X., Lobinska, G., Feldman, M., Dekel, E., Nowak, M. A., Pilpel, Y., Pauzner, Y., Barzel, B., & Pauzner, A. (2022) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1010391 · Cited by 21
Pramanik, A., Sharma, P. C., Patibandla, S., Gao, Y., Ruppa-Kasani, V., Goli, J., Kumar, A., Chatterjee, A., Sinha, S. S., Bates, J. T., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c00113 · Cited by 20
Structural basis of nanobodies neutralizing SARS-CoV-2 variants
Shi, Z., Li, X., Wang, L., Sun, Z., Zhang, H., Chen, X., Cui, Q., Qiao, H., Lan, Z., Zhang, X., et al. (2022) · Structure · doi:10.1016/j.str.2022.02.011 · Cited by 19
Deep Mutational Scanning of Viral Glycoproteins and Their Host Receptors
Narayanan, K. K., & Procko, E. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.636660 · Cited by 20
Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses
Li, X., Zhang, L., Chen, S., Ouyang, H., & Ren, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071479 · Cited by 21
Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
Yang, W., Greene, S. K., Peterson, E. R., Li, W., Mathes, R. W., Graf, L. E., Lall, R., Hughes, S., Wang, J., & Fine, A. D. (2022) · Science Advances · doi:10.1126/sciadv.abm0300 · Cited by 20
“In addition, a better understanding of factors contributing to the higher IFRs in certain variants is warranted to inform countermeasures (15, 16).”
BackgroundSARS-CoV-2: The Interplay Between Evolution and Host Immunity
Case, J. B., Jain, S., Suthar, M. S., & Diamond, M. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-083122-043054 · Cited by 28
Koehler, J., Ritzer, B., Weidlich, S., Gebhardt, F. E., Kirchhoff, C., Gempt, J., Querbach, C., Hoffmann, D., Haller, B., Schmid, R. M., et al. (2021) · Infection · doi:10.1007/s15010-021-01657-y · Cited by 17
Su, W., Sia, S. F., Schmitz, A. J., Bricker, T. L., Starr, T. N., Greaney, A. J., Turner, J. S., Mohammed, B. M., Liu, Z., Choy, K. T., et al. (2021) · mBio · doi:10.1128/mbio.02395-21 · Cited by 18
Self-citationUltrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance
Zou, J., Li, L., Zheng, P., Liang, W., Hu, S., Zhou, S., Wang, Y., Zhao, J., Yuan, D., Liu, L., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154987 · Cited by 22
Self-citationUpadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 19
Sokhansanj, B. A., & ROSEN, G. L. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105969 · Cited by 21
Boorla, V. S., Chowdhury, R., Ramasubramanian, R., Ameglio, B., Frick, R., Gray, J. J., & Maranas, C. D. (2022) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.26422 · Cited by 20
Sargsyan, K., Mazmanian, K., & Lim, C. (2023) · Scientific Reports · doi:10.1038/s41598-023-27649-6 · Cited by 17
Advancing Antibody Engineering through Synthetic Evolution and Machine Learning
Irvine, E. B., & Reddy, S. T. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300492 · Cited by 21
Biophysical principles predict fitness of SARS-CoV-2 variants
Wang, D., Huot, M., Mohanty, V., & Shakhnovich, E. I. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314518121 · Cited by 23
Sharif, N., Ahmed, S. N., Opu, R. R., Daullah, M. U., Khan, S., Talukder, A. A., Okitsu, S., Ushijima, H., Zhang, M., & Dey, S. K. (2021) · Epidemiology and Infection · doi:10.1017/s095026882100100x · Cited by 19
Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
Anichini, G., Terrosi, C., Savellini, G. G., Gandolfo, C., Franchi, F., & Cusi, M. G. (2021) · Vaccines · doi:10.3390/vaccines9050517 · Cited by 19
Makdasi, E., Zvi, A., Alcalay, R., Noy-Porat, T., Peretz, E., Mechaly, A., Levy, Y., Epstein, E., Chitlaru, T., Tennenhouse, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109679 · Cited by 23
Vanhove, B., Marot, S., So, R. T. Y., Gaborit, B. J., Evanno, G., Malet, I., Lafrogne, G., Mevel, E., Ciron, C., Royer, P., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.761250 · Cited by 20
Murano, K., Guo, Y., & Siomi, H. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210859 · Cited by 19
Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness
Al‐Tawfiq, J. A., Koritala, T., Alhumaid, S., Barry, M. A., Alshukairi, A. N., Temsah, M.-H. A., Mutair, A. S. A., Rabaan, A. A., Tirupathi, R., & Gautret, P. (2022) · Infection · doi:10.1007/s15010-022-01759-1 · Cited by 17
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062928 · Cited by 17
Modeling the evolution of SARS-CoV-2 under non-pharmaceutical interventions and testing
Gurevich, Y., Ram, Y., & Hadany, L. (2022) · Evolution Medicine and Public Health · doi:10.1093/emph/eoac013 · Cited by 12
Mills, M. G., Hajian, P., Bakhash, S. M., Xie, H. J., Mantzke, D., Zhu, H., Perchetti, G. A., Huang, M.-L. W., Pepper, G., Jerome, K. R., et al. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105218 · Cited by 17
Wang, H., Gan, M., Wu, B., Zeng, R., Wang, Z., Xu, J., Li, J., Zhang, Y., Cao, J., Chen, L., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28380 · Cited by 14
Self-citationDeep Mutational Scanning to Predict Escape from Bebtelovimab in SARS-CoV-2 Omicron Subvariants
Alcantara, M. C., Higuchi, Y., Kirita, Y., Matoba, S., & Hoshino, A. (2023) · Vaccines · doi:10.3390/vaccines11030711 · Cited by 20
COVID-19 mutations: An overview
Sarkar, M. S., & Madabhavi, I. (2024) · World Journal of Methodology · doi:10.5662/wjm.v14.i3.89761 · Cited by 25
Yin, R. M., Guest, J. D., Taherzadeh, G., Gowthaman, R., Mittra, I., Quackenbush, J., & Pierce, B. G. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009380 · Cited by 18
van der Straten, K., van Gils, M. J., de Taeye, S. W., & de Bree, G. J. (2022) · Frontiers in Medical Technology · doi:10.3389/fmedt.2022.867982 · Cited by 17
Logue, J., Johnson, R. M., Patel, N., Zhou, B., Maciejewski, S. M., Foreman, B. M., Zhou, H., Portnoff, A. D., Tian, J.-H., Rehman, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35606-6 · Cited by 21
Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyPreprint
Choudhary, M. C., Chew, K. W., Deo, R., Flynn, J. P., Regan, J., Crain, C. R., Moser, C., Hughes, M. D., Ritz, J., Ribeiro, R. M., et al. (2021) · medRxiv · doi:10.1101/2021.09.03.21263105 · Cited by 17
Self-citationAmanat, F., Strohmeier, S., Lee, W.-H., Bangaru, S., Ward, A. B., Coughlan, L., & Krammer, F. (2021) · mBio · doi:10.1128/mbio.01002-21 · Cited by 16
Kibler, K. V., Szczerba, M., Lake, D. F., Roeder, A. J., Rahman, M. M., Hogue, B. G., Wong, L.-Y. R., Perlman, S. M., Li, Y., & Jacobs, B. L. (2022) · Vaccines · doi:10.3390/vaccines10081172 · Cited by 17
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Liang, H., Wu, Y., Yau, V., Yin, H.-X., Lowe, S., Bentley, R., Ahmed, M. A., Zhao, W., & Sun, C. (2022) · Vaccines · doi:10.3390/vaccines10091538 · Cited by 18
Ling, Z., Yi, C., Sun, X., Yang, Z., & Sun, B. (2022) · Science China Life Sciences · doi:10.1007/s11427-022-2215-6 · Cited by 16
Hamdy, M. E., El‐Deeb, A. H., Hagag, N. M., Shahein, M. A., Alaidi, O., & Hussein, H. A. (2023) · International Journal of Veterinary Science and Medicine · doi:10.1080/23144599.2023.2222981 · Cited by 21
“● This mutation caused a resistance to (REGN10933) which is a mixture of antibodies [103,104].”
BackgroundKugathasan, R., Sukhova, K., Moshe, M., Kellam, P., & Barclay, W. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011545 · Cited by 16
Gayvert, K. M., McKay, S., Lim, W. K., Baum, A., Kyratsous, C. A., Copin, R., & Atwal, G. S. (2023) · npj Viruses · doi:10.1038/s44298-023-00007-z · Cited by 18
“For instance, while K417N/T mutations in the RBD increased immune escape 43,52 , it occurred at the fi tness cost of reduced ACE2 binding af fi nity.”
Nie, J., Xie, J., Liu, S., Wu, J., Liu, C., Li, J., Liu, Y., Wang, M., Zhao, H., Zhang, Y., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00292-z · Cited by 15
Self-citationLeach, A., Ilca, F. T., Akbar, Z., Ferrari, M., Bentley, E. M., Mattiuzzo, G., Onuoha, S. C., Miller, A., Ali, H., & Rabbitts, T. H. (2021) · Antiviral Research · doi:10.1016/j.antiviral.2021.105147 · Cited by 16
Kubik, S., Arrigo, N., Bonet, J., & Xu, Z. (2021) · Viruses · doi:10.3390/v13112114 · Cited by 17
Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
Hendy, M. A., Kaufman, S., & Ponga, M. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01081-0 · Cited by 20
Detection of Viruses by Probe-Gated Silica Nanoparticles Directly from Swab Samples
Tuna, B. G., Durdabak, D. B., Ercan, M. K., Doğan, S., Kavruk, M., Dursun, A. D., Tekol, S. D., Celik, C., & Özalp, V. C. (2022) · Talanta · doi:10.1016/j.talanta.2022.123429 · Cited by 16
Ma, Y., Wang, Y., Dong, C., Gonzalez, G. X., Zhu, W., Kim, J., Wei, L., Kang, S., & Wang, B. (2022) · Small · doi:10.1002/smll.202200836 · Cited by 14
Jugler, C., Sun, H., Nguyen, K., Palt, R., Felder, M., Steinkellner, H., & Chen, Q. (2022) · Plant Biotechnology Journal · doi:10.1111/pbi.13970 · Cited by 18
Advances in antibody discovery from human BCR repertoires
Xu, Z., Ismanto, H. S., Zhou, H., Saputri, D. S., Sugihara, F., & Standley, D. M. (2022) · Frontiers in Bioinformatics · doi:10.3389/fbinf.2022.1044975 · Cited by 19
Viral Evolution Shaped by Host Proteostasis Networks
Yoon, J., Patrick, J. E., Ogbunugafor, C. B., & Shoulders, M. D. (2023) · Annual Review of Virology · doi:10.1146/annurev-virology-100220-112120 · Cited by 14
Structure-Based Discovery of Thiosemicarbazones As SARS-CoV-2 Main Protease Inhibitors
Maltarollo, V. G., da Silva, E. B., Kronenberger, T., Andrade, M. M. S., Marques, G., Oliveira, N. J. C., Santos, L. H., Júnior, C. D. O. R., Martinho, A. C. C., Skinner, D., et al. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0034 · Cited by 16
Bhattacharya, M., Chatterjee, S., Lee, S., Dhama, K., & Chakraborty, C. (2023) · Drug Resistance Updates · doi:10.1016/j.drup.2023.101008 · Cited by 17
Immunology of SARS-CoV-2 infections and vaccines
Schenten, D., & Bhattacharya, D. (2021) · Advances in immunology · doi:10.1016/bs.ai.2021.08.002 · Cited by 15
Engelhart, E., Lopez, R. M., Emerson, R., Lin, C., Shikany, C., Guion, D., Kelley, M., & Younger, D. A. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac011 · Cited by 18
Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
Jaki, L., Weigang, S., Kern, L., Kramme, S., Wrobel, A., Grawitz, A. B., Nawrath, P., Martin, S., Dähne, T., Beer, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37591-w · Cited by 13
Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors
Park, S. B., Irvin, P., Hu, Z., Khan, M., Hu, X., Zeng, Q., Chen, C., Xu, M., Leek, M., Zang, R., et al. (2022) · mBio · doi:10.1128/mbio.03238-21 · Cited by 15
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c00124 · Cited by 18
Neutralizing and enhancing antibodies against SARS-CoV-2
Liu, Y., & Arase, H. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00233-7 · Cited by 14
Onigbinde, S. B., Reyes, C. D. G., Fowowe, M., Daramola, O. E., Atashi, M., Bennett, A. I., & Mechref, Y. S. (2023) · Biomolecules · doi:10.3390/biom13101467 · Cited by 16
Antibody-mediated spike activation promotes cell-cell transmission of SARS-CoV-2
Yu, S., Zheng, X., Zhou, Y. R., Gao, Y., Zhou, B., Zhao, Y., Li, T., Li, Y., Mou, J., Cui, X., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011789 · Cited by 16
Hussein, H. A. M., Thabet, A. A., Wardany, A. A., El-Adly, A. M., Ali, M. E., Hassan, M. E. A., Abdeldayem, M. A. B., Mohamed, A.-R. M. A., Sobhy, A., El‐Mokhtar, M. A., et al. (2024) · Virology Journal · doi:10.1186/s12985-024-02342-w · Cited by 22
“The double B.1.617 mutations in the spike protein RBD, E484Q, and L452R, are responsible for increasing transmission and infectivity, immune response evasion, and high affinity to the human (h) ACE2 receptors [139, 140].”
BackgroundInfluentialFrei, L., Gao, B., Han, J., Taft, J. M., Irvine, E. B., Weber, C. R., Kumar, R. K., Eisinger, B., Ignatov, A., Yang, Z., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01353-4 · Cited by 21
Sun, Z., Zheng, X., Ji, F., Zhou, M., Su, X., Ren, K., & Li, L. (2021) · Infectious Microbes & Diseases · doi:10.1097/im9.0000000000000071 · Cited by 14
Khairnar, P., Soni, M., Handa, M., Riadi, Y., Kesharwani, P., & Shukla, R. (2022) · Journal of drug targeting · doi:10.1080/1061186x.2022.2056187 · Cited by 16
Metadata
- Authors
- Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D.
- Affiliations
- Fred Hutch Cancer Center (US)
- University of Washington (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Bloom, Jesse D.
- ORCID
- Venue
- Science
- Published
- 2021-02-19
- Volume
- 371
- Issue
- 6531
- Pages
- 850-854
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963219
- OpenAlex
- W3125266951
- Cited by
- 743
- References
- 40
- Citations by year
- 2026: 31 · 2025: 37 · 2024: 56 · 2023: 104 · 2022: 232 · 2021: 279
- FWCI
- 53.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute (Investigator)
- National Institute of Allergy and Infectious Diseases (R01AI127893, R01AI141707)
- Bill and Melinda Gates Foundation (INV-004949)
- Damon Runyon Cancer Research Foundation (DRG-2381-19)
- Massachusetts Consortium for Pathogen Readiness
- Washington Research Foundation (Innovation Fellow)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, antibody escape, receptor binding domain, viral mutations, monoclonal antibodies, antibody binding, viral surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.